TriSalus Life Sciences, Inc.
TLSI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 59% | 49.3% | 47.6% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 86.1% | 85.9% | 81.8% | 85.8% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -122.9% | -316.9% | -377.2% | -280.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -112.9% | -320.7% | -380.6% | -343.4% |
| EPS Diluted | -1.25 | -2.23 | -1.59 | -0.92 |
| % Growth | 43.9% | -40.3% | -72.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |